ECO SCIENCE SOLUTIONS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ECO SCIENCE SOLUTIONS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $0 | May 15, 2025 |
| FY2025 | Jan 31, 2024 | $0 | May 15, 2025 |
| FY2024 | Jan 31, 2023 | $0 | Oct 16, 2024 |
| FY2021 | Jan 31, 2021 | $52.7K | Sep 8, 2022 |
| FY2021 | Jan 31, 2020 | $59.7K | Sep 8, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Jan 31, 2012 | $348 | Apr 30, 2012 |
| FY2011 | Jan 31, 2011 | $2.5K | Apr 30, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | ($1.10M) | May 15, 2025 |
| FY2025 | Jan 31, 2024 | ($1.24M) | May 15, 2025 |
| FY2024 | Jan 31, 2023 | ($1.80M) | Oct 16, 2024 |
| FY2021 | Jan 31, 2021 | ($106.3K) | Sep 8, 2022 |
| FY2021 | Jan 31, 2020 | ($1.87M) | Sep 8, 2022 |
| FY2020 | Jan 31, 2019 | ($4.78M) | Jul 7, 2020 |
| FY2019 | Jan 31, 2018 | ($22.88M) | Jun 28, 2019 |
| FY2018 | Jan 31, 2017 | ($33.63M) | Nov 19, 2018 |
| FY2017 | Jan 31, 2016 | ($909.7K) | May 1, 2017 |
| FY2016 | Jan 31, 2015 | ($1.09M) | Jun 22, 2016 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | ($1.03M) | May 15, 2025 |
| FY2025 | Jan 31, 2024 | ($1.17M) | May 15, 2025 |
| FY2024 | Jan 31, 2023 | ($1.73M) | Oct 16, 2024 |
| FY2020 | Jan 31, 2020 | ($1.49M) | Jul 7, 2020 |
| FY2020 | Jan 31, 2019 | ($4.21M) | Jul 7, 2020 |
| FY2019 | Jan 31, 2018 | ($22.68M) | Jun 28, 2019 |
| FY2018 | Jan 31, 2017 | ($24.85M) | Nov 19, 2018 |
| FY2017 | Jan 31, 2016 | ($727.8K) | May 1, 2017 |
| FY2016 | Jan 31, 2015 | ($1.07M) | Jun 22, 2016 |
| FY2015 | Jan 31, 2014 | ($88.8K) | May 1, 2015 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $331.6K | May 15, 2025 |
| FY2025 | Jan 31, 2024 | $404.9K | May 15, 2025 |
| FY2024 | Jan 31, 2023 | $781.8K | Oct 16, 2024 |
| FY2021 | Jan 31, 2021 | $153.3K | Sep 8, 2022 |
| FY2021 | Jan 31, 2020 | $157.8K | Sep 8, 2022 |
| FY2020 | Jan 31, 2019 | $657.9K | Jul 7, 2020 |
| FY2019 | Jan 31, 2018 | $670.5K | Jun 28, 2019 |
| FY2018 | Apr 16, 2017 | $185.0K | Nov 19, 2018 |
| FY2018 | Jan 31, 2017 | $305.1K | Nov 19, 2018 |
| FY2017 | Jan 31, 2016 | $74.8K | May 1, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jan 31, 2018 | $18.0K | Nov 19, 2018 |
| FY2018 | Jan 31, 2017 | $18.0K | Nov 19, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | ($319.8K) | May 15, 2025 |
| FY2025 | Jan 31, 2024 | ($358.7K) | May 15, 2025 |
| FY2024 | Jan 31, 2023 | ($694.4K) | Oct 16, 2024 |
| FY2021 | Jan 31, 2021 | ($388.3K) | Sep 8, 2022 |
| FY2021 | Jan 31, 2020 | ($787.1K) | Sep 8, 2022 |
| FY2020 | Jan 31, 2019 | ($2.42M) | Jul 7, 2020 |
| FY2019 | Jan 31, 2018 | ($2.70M) | Jun 28, 2019 |
| FY2018 | Jan 31, 2017 | ($366.0K) | Nov 19, 2018 |
| FY2017 | Jan 31, 2016 | ($72.9K) | May 1, 2017 |
| FY2016 | Jan 31, 2015 | ($140.1K) | Jun 22, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jan 31, 2018 | $13.3K | Jun 28, 2019 |
| FY2018 | Jan 31, 2017 | $2.3K | Nov 19, 2018 |
| FY2012 | Jan 31, 2013 | ($1.7K) | Dec 12, 2013 |
| FY2011 | Jan 31, 2012 | $7.8K | Apr 30, 2012 |
| FY2011 | Jan 31, 2011 | $7.8K | Apr 30, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $107.3K | May 15, 2025 |
| FY2025 | Jan 31, 2024 | $102.1K | May 15, 2025 |
| FY2024 | Jan 31, 2023 | $14.5K | Oct 16, 2024 |
| FY2021 | Jan 31, 2021 | $4.9K | Sep 8, 2022 |
| FY2021 | Jan 31, 2020 | $61.1K | Sep 8, 2022 |
| FY2020 | Jan 31, 2019 | $154.7K | Jul 7, 2020 |
| FY2019 | Jan 31, 2018 | $158.6K | Jun 28, 2019 |
| FY2018 | Jan 31, 2017 | $246.6K | Nov 19, 2018 |
| FY2017 | Jan 31, 2016 | $6.7K | May 1, 2017 |
| FY2016 | Jan 31, 2015 | $13.3K | Jun 22, 2016 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $16.67M | May 15, 2025 |
| FY2025 | Jan 31, 2024 | $15.56M | May 15, 2025 |
| FY2024 | Jan 31, 2023 | $14.23M | Oct 16, 2024 |
| FY2021 | Jan 31, 2021 | $11.00M | Sep 8, 2022 |
| FY2021 | Jan 31, 2020 | $11.31M | Sep 8, 2022 |
| FY2020 | Jan 31, 2019 | $9.53M | Jul 7, 2020 |
| FY2019 | Jan 31, 2018 | $4.85M | Jun 28, 2019 |
| FY2018 | Jan 31, 2017 | $1.02M | Nov 19, 2018 |
| FY2017 | Jan 31, 2016 | $763.2K | May 1, 2017 |
| FY2016 | Jan 31, 2015 | $523.8K | Jun 22, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | ($16.56M) | May 15, 2025 |
| FY2025 | Jan 31, 2024 | ($15.46M) | May 15, 2025 |
| FY2025 | Jan 31, 2023 | ($14.22M) | May 15, 2025 |
| FY2024 | Jan 31, 2022 | ($12.42M) | Oct 16, 2024 |
| FY2021 | Jan 31, 2021 | ($10.99M) | Sep 8, 2022 |
| FY2021 | Jan 31, 2020 | ($11.25M) | Sep 8, 2022 |
| FY2021 | Jan 31, 2019 | ($9.38M) | Sep 8, 2022 |
| FY2020 | Jan 31, 2018 | ($4.69M) | Jul 7, 2020 |
| FY2019 | Jan 31, 2017 | ($774.4K) | Jun 28, 2019 |
| FY2018 | Jan 31, 2016 | ($756.5K) | Nov 19, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 21, 2017 | $18.40M | Nov 19, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | ($78.73M) | May 15, 2025 |
| FY2025 | Jan 31, 2024 | ($77.62M) | May 15, 2025 |
| FY2024 | Jan 31, 2023 | ($76.38M) | Oct 16, 2024 |
| FY2021 | Jan 31, 2021 | ($73.15M) | Sep 8, 2022 |
| FY2021 | Jan 31, 2020 | ($73.05M) | Sep 8, 2022 |
| FY2020 | Jan 31, 2019 | ($71.18M) | Jul 7, 2020 |
| FY2019 | Jan 31, 2018 | ($66.40M) | Jun 28, 2019 |
| FY2018 | Jan 31, 2017 | ($43.52M) | Nov 19, 2018 |
| FY2017 | Jan 31, 2016 | ($9.89M) | May 1, 2017 |
| FY2016 | Jan 31, 2015 | ($8.98M) | Jun 22, 2016 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $2.8K | May 15, 2025 |
| FY2025 | Jan 31, 2024 | $2.1K | May 15, 2025 |
| FY2024 | Jan 31, 2023 | $526 | Oct 16, 2024 |
| FY2020 | Jan 31, 2020 | $2.9K | Jul 7, 2020 |
| FY2020 | Jan 31, 2019 | $1.6K | Jul 7, 2020 |
| FY2020 | Jan 31, 2018 | $2.1K | Jul 7, 2020 |
| FY2019 | Jan 31, 2017 | $244.1K | Jun 28, 2019 |
| FY2018 | Jan 31, 2016 | $6.7K | Nov 19, 2018 |
| FY2017 | Jan 31, 2015 | $13.3K | May 1, 2017 |
| FY2016 | Jan 31, 2014 | $5.7K | Jun 22, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | 52.96M | May 15, 2025 |
| FY2025 | Jan 31, 2024 | 52.96M | May 15, 2025 |
| FY2024 | Jan 31, 2023 | 52.96M | Oct 16, 2024 |
| FY2021 | Jan 31, 2021 | 52.96M | Sep 8, 2022 |
| FY2021 | Jan 31, 2020 | 47.56M | Sep 8, 2022 |
| FY2020 | Jan 31, 2019 | 47.56M | Jul 7, 2020 |
| FY2019 | Jan 31, 2018 | 46.56M | Jun 28, 2019 |
| FY2018 | Jan 31, 2017 | 45.33M | Nov 19, 2018 |
| FY2017 | Jan 31, 2016 | 28.23M | May 1, 2017 |
| FY2016 | Jan 31, 2015 | 30.64M | Jun 22, 2016 |